OnCo
trialsTrialPositive

COG ANBL0532

COG ANBL0532 showed that two transplants in a row beat one in high-risk neuroblastoma.

3-year EFS 61.6% vs 48.4% (JAMA 2019); with subsequent anti-GD2 immunotherapy, 3-year EFS 73.7% vs 56.0%. OS not significantly different at 3 years. Tandem transplant became the North American standard.

Setting
High-risk neuroblastoma: tandem vs single autologous transplant after induction
Phase
Phase 3
Sponsor
Children's Oncology Group
Registry
Headline result
3-year EFS 61.6% vs 48.4%.
Reported
2016
Enrolled
652

Outcomes

1top
In plain words
What these results mean for people, not percentages
652 people took part
Event-free survival at 3 yearsprimarysurrogate endpoint
  • 61.6 vs 48.4 out of 100 free of a major event at 3 years with Tandem transplant compared with Single transplant; 13.2 more per 100.
  • Roughly one extra person helped for every 8 treated. That is a rough figure taken from the two percentages, not a guarantee for any one person.
  • The p-value (0.006) says a difference this large would rarely happen by chance; it does not say how large or how useful the difference is.
  • This is a surrogate endpoint: it measures the cancer being controlled or absent on scans and tests, which often, but not always, translates into living longer.
  • These results apply to the people the trial enrolled: High-risk neuroblastoma: tandem vs single autologous transplant after induction. People in a different situation may not see the same effect.

Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.

652 participants enrolled.

Event-free survival at 3 yearsprimary
· p = 0.006
Tandem transplant61.6 of 100
n = 176
Single transplant48.4 of 100
n = 179
Source
EndpointArmnValueHR (95% CI)pSource
Event-free survival at 3 yearsprimaryTandem transplant17661.6%0.006link
Single transplant17948.4%

Connected

5top